Brief: Anavex Life Sciences Announces Completion Of Anavex(®)2-73 (Blarcamesine) Excellence Phase 2/3 Rett Syndrome Clinical Trial
06/06/2023 12:54
June 6 (Reuters) - Anavex Life Sciences Corp AVXL.O :
* ANAVEX LIFE SCIENCES ANNOUNCES COMPLETION OF ANAVEX(®)2-73
(BLARCAMESINE) EXCELLENCE PHASE 2/3 RETT SYNDROME CLINICAL TRIAL
Source text for Eikon: ID:nGNX4L4ZrV
Further company coverage: AVXL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anavex Life Sciences
See all newsBrief: Anavex Provides Corporate Update, Announces Completion Of Clinical Conduct Of Adme And Ddi Clinical Studies
Brief: Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome
Brief: Glass Lewis Recommends Anavex Stockholders To Vote For PVG’s Director Nominees
Brief: PVG Calls For Replacing Anavex Board, Hiring "Experienced" CEO
Brief: Pvg Asset Management- Nominates Six Director Candidates For Anavex Board